Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”

July 13, 2021

Significance of Early and Broad Testing of Tumor Mutations

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss how testing for tumor mutations early and broadly may lead to better treatment outcomes.

December 3, 2013

The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma

In the first WCMC clinical commentary entitled, The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma, Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD; Aleksander Sekulic, MD, PhD discuss how the hedgehog pathway plays a critical role in developing basal cell carcinoma and how inhibitors are providing new strategies [ Read More ]